Neoplastic synovial lining cells that coexpress podoplanin and CD90 overproduce CSF‐1, driving tenosynovial giant cell tumor

2021 ◽  
Author(s):  
Andrew C. Chandler ◽  
Mohamed Yakoub ◽  
Tomohiro Fujiwara ◽  
Laura T. Donlin ◽  
Paul Edward Purdue ◽  
...  
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Cell Tumor ◽  
Synovial Lining ◽  
Tenosynovial Giant Cell Tumor ◽  
Synovial Lining Cells

CLINICAL AND MORPHOLOGICAL CORRELATIONS AND HISTOPATHOLOGY OF JOINT DAMAGE IN PATIENTS WITH DIFFUSE-TYPE TENOSYNOVIAL GIANT CELL TUMOR

2019 ◽  
Vol 72 (12) ◽  
Author(s):  
Olena O Dyadyk ◽  
Anastasiia Hryhorovska
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Cell Size ◽  
Giant Cells ◽  
Cell Tumor ◽  
Multinucleated Giant Cells ◽  
Diffuse Type ◽  
Association Coefficient ◽  
Mean Values ◽  
Tenosynovial Giant Cell Tumor

Introduction: Tenosynovial giant cell tumor (TSGCT) (synonym – pigmented villonodular synovitis) – is a rare benign proliferative lesion of the synovial sheath, localized in the joint capsule, bursa or tendon sheath and characterized by locally destructive growth. Depending on the prevalence within the joint elements, the presence of a capsule around the tumor, histophotographic features of cell structure and clinical behavior TSGCT can be divided to localized or diffuse type. The aim of the study was researching of histopathological properties of diffuse-type TSGCT, determine the parameters its morphological indicators and to find out the correlation between these morphological and clinical parameters. Materials and methods: The research material was used biopsy (resect) of pathological lesions from 50 patients who were diagnosed and histologically verified diffuse-type TSGCT. Microscopic examinations of the stained sections and their photo archiving were carried out with use of a Olympus-CX 41 light optical microscope. Group measurable parameters (mean values and Pearson tetrachoric index (association coefficient) were calculated in groups of comparison for morphological and clinical indices of TSGCT. The mean values were compared by Student’s test, P value of ≤0.1 was considered statistically significant. Results:Correlation analysis of indicators that accounted for the pairs of cases «clinic – morphology» revealed the relationships, that had the highest parameters of the association coefficient between such indicators: «presence of villous growths» - «severity of hemosiderosis» (if hypertrophied synovial villi available, with vascular injection and pronounced proliferation of synovial cells, there is also a significant accumulation of hemosiderin pigment); «presence of villous growths» - «type of predominant cellular proliferates» (if cells of TSGCT diffuse type consists of monotonous sheets of stromal cells, with uniform, oval to reniform nuclei, the proliferation of villi in synovial layer is non-distinctive); «presence of nodes» - «kind of stroma» (if nodes predominate, their histological structure is mainly represented by polymorphic clusters of synovitis cells in the form of cells, strands, chains, solid formations, among immature connective tissue with low hyalinosis); «cell size (area, cm²)» - «severity of haemosiderosis» and «cell size (area, cm²)» - «the number of multinucleated giant cells» (there is a pronounced deposition of pigment and accumulation of osteoclast-like multinucleated giant cells type, although usually their number is relatively small compared to the localized type of TSGCT). Conclusions: Morphological parameters, that we have identified, characterize pathological changes in the tissues of TSGCT; careful analysis of the frequency of their occurrence in the different comparison groups made it possible to establish intergroup differences and correlations between individual indicators, which were previously unknown or not obvious. Our study was determine to analyze of incidence rates and correlation relationships, revealed some previously unknown differences and dependencies that are important for understanding the pathogenesis, improvement of diagnosis and prognosis of diffuse-type TSGCT.

scholarly journals Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial

2021 ◽  
pp. 1-7
Author(s):  
Michiel Van De Sande ◽  
William D Tap ◽  
Heather L Gelhorn ◽  
Xin Ye ◽  
Rebecca M Speck ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Randomized Clinical Trial ◽  
Physical Functioning ◽  
Cell Tumor ◽  
Tenosynovial Giant Cell Tumor

scholarly journals Tenosynovial giant cell tumor of the distal tibiofibular joint

2021 ◽  
Vol 16 (4) ◽  
pp. 950-955
Author(s):  
Stephanie D. Zarate ◽  
David M. Joyce ◽  
Ana C. Belzarena
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Cell Tumor ◽  
Tenosynovial Giant Cell Tumor ◽  
Tibiofibular Joint

Intramuscular Tenosynovial Giant Cell Tumor Harboring a Novel CSF1-CD96 Fusion Transcript

2021 ◽  
pp. 106689692110498
Author(s):  
Haider Mejbel ◽  
Gene P. Siegal ◽  
Shi Wei
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Gene Rearrangement ◽  
Fusion Transcript ◽  
Cell Tumor ◽  
Molecular Profile ◽  
Small Subset ◽  
Fusion Partner ◽  
Giant Cell Tumors ◽  
Tenosynovial Giant Cell Tumor

Tenosynovial giant cell tumors typically arise in the synovium of joints, bursae, or tendon sheaths. They may occur in an intra- or extra-articular location and can be divided into localized and diffuse types. The neoplastic nature of the lesion has been supported by a recurrent CSF1 gene rearrangement in a small subset of lesional cells, of which the most common fusion partner is COL6A3. Herein, we report a case of intramuscular localized tenosynovial giant cell tumor harboring a novel CSF1-CD96 fusion transcript, thus expanding the molecular profile of this tumor.

scholarly journals Tenosynovial Giant Cell Tumor in the Midfoot Treated With Femoral Head Allograft Reconstruction

2018 ◽  
Vol 57 (1) ◽  
pp. 172-178 ◽  
Author(s):  
Daniel J. Fuchs ◽  
Paul J. Switaj ◽  
Terrance D. Peabody ◽  
Anish R. Kadakia
Keyword(s):  
Femoral Head ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Cell Tumor ◽  
Allograft Reconstruction ◽  
Tenosynovial Giant Cell Tumor

scholarly journals Tenosynovial Giant Cell Tumor of the Pes Anserine Bursa with Bone Marrow Extension into the Tibia: A Case Report

2016 ◽  
Vol 75 (4) ◽  
pp. 322 ◽  
Author(s):  
Soo Jung Kim ◽  
Yong-Koo Kang ◽  
Chang Young Yoo ◽  
Jee Young Kim
Keyword(s):  
Bone Marrow ◽  
Case Report ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Cell Tumor ◽  
Tenosynovial Giant Cell Tumor

Giant Cell Poor Extra-Articular Diffuse-Type Tenosynovial Giant Cell Tumor With Extensive Desmin Expression: A Potential Diagnostic Pitfall With Cytogenetic Confirmation

2018 ◽  
Vol 27 (1) ◽  
pp. 59-61
Author(s):  
Liurka Lopez ◽  
Karen Schoedel ◽  
Ivy John
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Mononuclear Cells ◽  
Giant Cells ◽  
Cell Tumor ◽  
Diffuse Type ◽  
Tenosynovial Giant Cell Tumor ◽  
Diagnostic Pitfall

Diffuse-type tenosynovial giant cell tumor can rarely present as an entirely extra-articular mass, which can be misdiagnosed as a sarcoma especially when giant cells are absent, dominated by large dendritic mononuclear cells, and desmin expression is extensive.

Localized Tenosynovial Giant Cell Tumor

2020 ◽  
pp. 507-508
Author(s):  
Simone Mocellin
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Cell Tumor ◽  
Tenosynovial Giant Cell Tumor

scholarly journals Tenosynovial Giant Cell Tumor

2020 ◽  
pp. 773-773
Author(s):  
Simone Mocellin
Keyword(s):  
Giant Cell Tumor ◽  
Giant Cell ◽  
Cell Tumor ◽  
Tenosynovial Giant Cell Tumor

scholarly journals Tenosynovial Giant-Cell Tumor Presenting as Septic Arthritis of the Knee

2021 ◽  
Vol 5 (4) ◽  
Author(s):  
Gregory E. Lausé ◽  
Michael D. Baird ◽  
Kevin P. Krul ◽  
Craig R. Bottoni
Keyword(s):  
Septic Arthritis ◽  
Giant Cell Tumor ◽  
Giant Cell ◽  
Cell Tumor ◽  
Tenosynovial Giant Cell Tumor
Sign in / Sign up

Export Citation Format

Share Document